Skip to main content

Table 2 Subject demographic characteristics and severity classifications: validation data

From: Using medication utilization information to develop an asthma severity classification model

Variables All asthma, (n = 3628) Classified by Asthma severity, n (%) p-value
Stage 1 (n = 2276, 62.73%) Stage 2 (n = 230, 6.34%) Stage 3 (n = 807, 22.24%) Stage 4 (n = 315, 8.68%)
Gender, n (%)       0.7073
 Female 2107 (58.08) 1309 (57.51) 141 (61.30) 472 (58.49) 185 (58.73)  
 Male 1521 (41.92) 967 (42.49) 89 (38.70) 335 (41.51) 130 (41.27)  
Age, n (%)       <.0001
 18–34 874 (24.09) 503 (22.10) 72 (31.30) 221 (27.39) 78 (24.76)  
 35–44 586 (16.15) 346 (15.20) 40 (17.39) 145 (17.97) 55 (17.46)  
 45–54 686 (18.91) 430 (18.89) 48 (20.87) 150 (18.59) 58 (18.41)  
 55–64 588 (16.21) 371 (16.30) 41 (17.83) 123 (15.24) 53 (16.83)  
65 894 (24.64) 626 (27.50) 29 (12.61) 168 (20.82) 71 (22.54)  
CCI, Mean (SD) 0.41 (0.86) 0.44 (0.88) 0.30 (0.69) 0.38 (0.86) 0.35 (0.76) 0.0252
Obesity, n (%) 18 (0.50) 12 (0.53) 0 (0.00) 4 (0.50) 2 (0.63) 0.8377
Sinusitis, n (%) 35 (0.96) 21 (0.92) 4(1.74) 7(0.87) 3(0.95) 0.5970
GERD, n (%) 10 (0.28) 6 (0.26) 0 (0.00) 4 (0.50) 0 (0.00) 0.5579
Medication utilization, n (%)
 ICS/LABA 853 (23.51) 0 (0.00) 0 (0.00) 658 (81.54) 195 (61.90) <.0001
 ICS 331 (9.12) 0 (0.00) 227 (98.70) 90 (11.15) 14 (4.44) <.0001
 OCS 358 (9.87) 0 (0.00) 0 (0.00) 188 (23.30) 170 (53.97) <.0001
 SABA 870 (23.98) 428 (18.80) 82 (35.65) 299 (37.05) 61 (19.37) <.0001
 SAMA 133 (3.67) 66 (2.90) 9 (3.91) 46 (5.70) 12 (3.81) 0.0040
 SABA/SAMA 119 (3.28) 51 (2.24) 9 (3.91) 46 (5.70) 13 (4.13) <.0001
# of patient having acute exacerbation, n (%) 361 (9.95) 186 (8.17) 21 (9.13) 118 (14.62) 36 (11.43) <.0001
 Hospitalization 59 (1.63) 26 (1.14) 1 (0.43) 21 (2.60) 11 (3.49) 0.0007
 Emergency department visit 174 (4.80) 83 (3.65) 11 (4.78) 66 (8.18) 14 (4.44) <.0001
 Short-acting drug 230 (6.34) 121 (5.32) 11 (4.78) 74 (9.17) 24 (7.62) 0.0008
  1. CCI Charlson Comorbidity Index, GERD Gastroesophageal reflux disease, ICS inhaled corticosteroid, OCS oral corticosteroid, SABA short-acting inhaled β2-agonist, LABA long-acting inhaled β2-agonist, SAMA short-acting muscarinic receptor antagonists